Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer

BACKGROUND The purpose of the current study was to describe the outcomes of patients with human epidermal growth factor receptor 2 (HER2)‐overexpressed/amplified (HER2+) early breast cancer who received adjuvant or neoadjuvant trastuzumab‐based therapy and were subsequently retreated with trastuzuma...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2014-07, Vol.120 (13), p.1932-1938
Hauptverfasser:	Murthy, Rashmi K., Varma, Ankur, Mishra, Priyankana, Hess, Kenneth R., Young, Elliana, Murray, James L., Koenig, Kimberly H., Moulder, Stacy L., Melhem‐Bertrandt, Amal, Giordano, Sharon H., Booser, Daniel, Valero, Vicente, Hortobagyi, Gabriel N., Esteva, Francisco J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomarkers, Tumor - analysis breast neoplasms Breast Neoplasms - chemistry Breast Neoplasms - drug therapy Breast Neoplasms - pathology Chemotherapy, Adjuvant Disease-Free Survival drug resistance Female Gene Expression Regulation, Neoplastic Gynecology. Andrology. Obstetrics human epidermal growth factor receptor 2 (HER2) Humans Kaplan-Meier Estimate Mammary gland diseases Medical sciences metastasis Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoadjuvant Therapy - methods Neoplasm Grading Neoplasm Staging Odds Ratio outcomes Predictive Value of Tests Prognosis Proportional Hazards Models Receptor, ErbB-2 - analysis Retrospective Studies Trastuzumab Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!